ArticleFrontiers in pharmacology2025
The therapeutic efficacy of radical resection for hepatocellular carcinoma varies markedly by tumor location: a retrospective real-world study.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: This study aims to explore the impact of the distance between the tumor and the main trunk or first branch of the portal vein on the prognosis of hepatocellular carcinoma (HCC) patients undergoing radical resection. Methods: This study retrospectively evaluated HCC patients who underwent radical resection between 1 January 2018 and 30 September 2024. Tumors were classified into two categories based on their location: central tumors and peripheral tumors. Central tumors were defined as those located within 2 cm of the main trunk or first branch of the portal vein, while the remaining tumors were classified as peripheral tumors. Recurrence-free survival (RFS) and overall survival (OS) were compared between the two groups. Univariate and multivariate COX analyses were conducted to identify factors associated with RFS and OS. Propensity score matching (PSM) was employed to eliminate intergroup differences for further validation. Results: A total of 667 HCC patients undergoing radical resection were initially enrolled. Through PSM, 247 patients were successfully matched in each comparative group. In the PSM cohort, the median RFS (mRFS) for patients with central tumors was 23.00 months (95% CI, 18.01-27.99 months), while the mRFS for those with peripheral tumors was 30.50 months (95% CI, 26.17-34.83 months) (p = 0.004). The median OS was 56.00 months (95% CI, 52.10-59.90 months) for central tumors and 72.00 months (95% CI, 67.37-76.63 months) for peripheral tumors (p = 0.043). Multivariate COX analysis confirmed that the distance of less than 2 cm between the tumor and the main trunk or first branch of the portal vein was an independent risk factor for RFS and OS in patients undergoing radical resection for HCC (HR: 1.744, p < 0.001; 1.728, p < 0.001, respectively). Conclusion: The distance between the tumor and the main portal vein trunk or first branch correlates with the prognosis of hepatocellular carcinoma patients undergoing radical resection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.